Drugs / VERT-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06669117 | Oct 2024 → Oct 2030 expected | cancer | Pierre Fabre Laboratories | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-10-24 | Pierre Fabre Medicament | Dosing of the first patient in the phase I/II trial evaluating PFL-002/VERT-002, a targeted therapy in oncology pierre-fabre.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VERT-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06669117 ↗ |
| Route | Intravenous | “Route of Administration: Intravenous” NCT06669117 ↗ |